NCT06973668View on ClinicalTrials.gov

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions

AML

Interventions

DRUG

Mycophenolate Mofetil

15 mg/kg/dose (max: 1,000mg/dose) IV/PO three times daily

DRUG

Ruxolitinib

5 mg PO every 12 hours

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT06973668 - A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease | Biotech Hunter | Biotech Hunter